Clinical Trials Logo

Gastritis clinical trials

View clinical trials related to Gastritis.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT05238181 Enrolling by invitation - Autoimmune Diseases Clinical Trials

Pyloric or Pseudopyloric Metaplasia of the Corpus Mucosa in Autoimmune Gastritis

PM_in_AIG
Start date: January 1, 2022
Phase:
Study type: Observational

The study is aimed to investigate the different rates of pyloric/ pseudopyloric metaplasia or spasmolytic polypeptide-expressing metaplasia (SPEM) of corpus between autoimmune gastritis and H. pylori-infected non-ulcer dyspepsia.

NCT ID: NCT05021029 Enrolling by invitation - Clinical trials for Intestinal Metaplasia

A Study of Pre-Malignant Gastric Conditions

Start date: July 13, 2021
Phase:
Study type: Observational

To establish a prospective cohort of individuals diagnosed with gastric pre-malignant conditions (chronic gastritis, atrophic gastritis, autoimmune gastritis, intestinal metaplasia, intestinal dysplasia) to monitor and study disease progression. The Investigators will like to survey cohort participants for lifestyle behaviors and environmental exposures associated with gastric pre-malignancy and cancer. Analyzing patient biospecimens to identify and characterize host and microbiome biomarkers associated with initiation and progression of gastric pre-malignancies.

NCT ID: NCT03802318 Enrolling by invitation - Clinical trials for Helicobacter Pylori Infection

Daily Four Times or Two Times Usage of PPI and Amoxicillin for the First or Second Line H. Pylori Eradication

Start date: January 2, 2019
Phase: N/A
Study type: Interventional

The hypothesis and plan of the current study are: 1. One induction phase of high dose PPI before eradication will increase intragastric pH and induce H. pylori into an active replicative status. Active replicative status will enhance the bactericidal effect of amoxicillin. Rabeprazole (20 mg) four times per day (qid) for 3 days will be used for induction in this study. 2. High dose PPI will provide adequate plasma concentration irrespective of the CYP2C19 genotype of the population. Here rabeprazole (20 mg) qid will be applied as high dose PPI. 3. High frequent amoxicillin usage (500 mg, qid) will maintain plasma concentration above the MIC. Amoxicillin (500 mg) qid will be described for total 14 days. 4. In the rescue therapy, add levofloxacin on high dose dual therapy will increase the eradication rate than single high dose dual therapy. A combination of levofloxacin and high dose dual therapy will also have a better eradication rate than the common used levofloxacin based triple therapy.

NCT ID: NCT03228095 Enrolling by invitation - Colorectal Cancer Clinical Trials

Volatiles in Breath and Headspace Analysis - Diagnostic Markers

Volatolome
Start date: July 24, 2017
Phase:
Study type: Observational

Detection of Volatile Organic Compounds (VOC) directly from tissue by headspace analysis (skin, surgery material, other tissue) and exhaled breath is feasible using affordable user-friendly novel nano-chemo sensors that can accurately be used for screening and monitoring purpose